Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
1.
Hepatol Int ; 16(5): 1094-1104, 2022 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-35657479

RESUMEN

BACKGROUND AND AIMS: Little is known regarding the epidemiology and outcomes of patients with primary sclerosing cholangitis (PSC) in Australia. We, therefore, evaluated the epidemiology and clinical outcomes of PSC in a large cohort of Australian patients and compared these to the general population. METHODS: We conducted a multicentre, retrospective cohort study of PSC patients at nine tertiary liver centers across three Australian states, including two liver transplant centers. RESULTS: A total of 413 PSC patients with 3,285 person-years of follow-up were included. Three hundred and seventy-one (90%) patients had large duct PSC and 294 (71%) had associated inflammatory bowel disease. A total of 168 (41%) patients developed cirrhosis (including 34 at the time of PSC diagnosis) after a median of 15.8 (95% CI 12.4, NA) years. The composite endpoint of death or liver transplantation occurred in 49 (12%) and 78 (19%) patients, respectively, with a median transplant-free survival of 13.4 (95% CI 12.2-15) years. Compared to the general population, PSC accounted for a 240-fold increased risk of development of cholangiocarcinoma (CCA) and CCA-related death. CCA risk was increased with older age of PSC diagnosis, presence of dominant stricture and colectomy. Compared to same-aged counterparts in the general population, PSC patients who were diagnosed at an older age or with longer disease duration had reduced relative survival. CONCLUSION: In this large retrospective cohort study of PSC patients in Australia, increased age and time from diagnosis was associated with increased mortality and morbidity particularly from CCA and development of cirrhosis, necessitating need for liver transplant.


Asunto(s)
Neoplasias de los Conductos Biliares , Colangiocarcinoma , Colangitis Esclerosante , Australia/epidemiología , Neoplasias de los Conductos Biliares/complicaciones , Conductos Biliares Intrahepáticos/patología , Colangiocarcinoma/complicaciones , Colangitis Esclerosante/complicaciones , Colangitis Esclerosante/epidemiología , Estudios de Cohortes , Humanos , Cirrosis Hepática/complicaciones , Estudios Retrospectivos
3.
Intern Med J ; 45(2): 214-7, 2015 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-25650536

RESUMEN

Stomal variceal bleeding is a rare but life-threatening complication of cirrhosis. As it is an uncommon condition, there is little evidence on the optimum treatment. We report a case of parastomal variceal bleeding in a cirrhotic and haemodynamically unstable patient. The bleeding had failed to respond to local therapy and was not amenable to transjugular intrahepatic portosystemic shunting. The varix was successfully treated under radiological guidance embolisation in conjunction with Fibrovein (STD Pharmaceuticals, UK) sclerosis. We propose that Fibrovein sclerosis through angiography should be considered as an initial treatment option in patients with parastomal variceal bleeding who are not candidates for transjugular intrahepatic portosystemic shunting.


Asunto(s)
Colostomía/efectos adversos , Várices Esofágicas y Gástricas/terapia , Hemorragia Gastrointestinal/terapia , Cirrosis Hepática Alcohólica/complicaciones , Neoplasias del Colon Sigmoide/cirugía , Anciano , Colectomía/métodos , Embolización Terapéutica/métodos , Várices Esofágicas y Gástricas/complicaciones , Estudios de Seguimiento , Hemorragia Gastrointestinal/etiología , Hemorragia Gastrointestinal/fisiopatología , Humanos , Unidades de Cuidados Intensivos , Cirrosis Hepática Alcohólica/diagnóstico , Masculino , Recurrencia , Medición de Riesgo , Escleroterapia/métodos , Neoplasias del Colon Sigmoide/complicaciones , Neoplasias del Colon Sigmoide/diagnóstico , Estomas Quirúrgicos/efectos adversos , Resultado del Tratamiento
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA